Infections cutanées staphylococciques et streptococciques

  • Ziad Reguiaï
  • Philippe Bernard

Abstrait

Les staphylocoques sont les principaux germes bactériens composant la flore cutanée normale. En revanche, le portage de streptocoques et notamment de Streptococcus pyogenes est transitoire et s’observe le plus souvent en peau lésée. Les infections cutanées secondaires à ces deux bactéries cocci à Gram positif surviennent soit directement en raison de leur caractère pathogène au sein du tissu cutané, soit indirectement par la libération de toxines agissant comme des superantigènes potentiellement responsables de chocs toxiques. Les tableaux cliniques ne permettent pas toujours de distinguer les infections streptococciques des infections staphylococciques et leur gravité varie selon la profondeur de l’atteinte cutanée et des structures impliquées (follicule pileux, épiderme, hypoderme...) (tableau 23.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Neu HC. The crisis in antibacterial resistance. Science 1992; 257:1064–1073.PubMedCrossRefGoogle Scholar
  2. 2.
    Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(Suppl 53):9–12.Google Scholar
  3. 3.
    Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520–532.PubMedCrossRefGoogle Scholar
  4. 4.
    Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5:751–562.PubMedCrossRefGoogle Scholar
  5. 5.
    Kuroda M, Ohta T, Uchiyama I et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 200; 357:1225–1240.Google Scholar
  6. 6.
    Skinner D, Keefer CS. Significance of bacteraemia caused by staphylococcus. Arch Intern Med 1941; 68:851–875.Google Scholar
  7. 7.
    Katayama Y, Zhang H, Hong D, Chambers H. Jumping the barrier to b-lactam resistance in Staphylococcus aureus. J Bacteriol 2003; 185:5465–5472.PubMedCrossRefGoogle Scholar
  8. 8.
    Jevons MP, Coe AW, Parker MT. Celbeninresistants staphylococci. Methicillin resistance in staphylococci. Lancet 1963; 1:904–907.CrossRefGoogle Scholar
  9. 9.
    Zetola N, Francis J, Nuermberger E, Bishai W. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Inf Dis 2005; 5:275–286.CrossRefGoogle Scholar
  10. 10.
    Boyce JM, Cookson B, Christiansen K et al. Meticillin-resistant Staphylococcus aureus. Lancet Inf Dis 2005; 5:653–663.CrossRefGoogle Scholar
  11. 11.
    Robinson DA, Kearns AM, Holmes A et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillinresistant clone. Lancet 2005; 365:1256–1258.PubMedCrossRefGoogle Scholar
  12. 12.
    Wielders C, Vriens M, Brisse S et al. In-vivo transfer of mecA DNA to Staphylococcus aureus. Lancet 2001; 357:1674–1675.PubMedCrossRefGoogle Scholar
  13. 13.
    Oliveira D, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillinresistant Staphylococcus aureus. Lancet Infect Dis 2002; 2:180–189.PubMedCrossRefGoogle Scholar
  14. 14.
    Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51:1109–1117.PubMedCrossRefGoogle Scholar
  15. 15.
    Naimi T, LeDell K, Como-Sabetti K et al. Comparison of Community-and Health Care-Associated Methicillin-Resistant Staphylococcus aureus Infection. JAMA 2003; 290:2976–2984.PubMedCrossRefGoogle Scholar
  16. 16.
    John CC. Vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 341:207–208.PubMedCrossRefGoogle Scholar
  17. 17.
    Bernard P. Du bon usage des antibiotiques locaux en dermatologie. Ann Dermatol Venereol 2004; 131:941–943.PubMedCrossRefGoogle Scholar
  18. 18.
    Speller D, Johnson A, James D et al. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989–1995. Lancet 1997; 350:323–325.PubMedCrossRefGoogle Scholar
  19. 19.
    Lancefield RC. A serological differentiation of human and other groups of haemolytic streptococci. J Exp Med 1933; 57:571–595.CrossRefGoogle Scholar
  20. 20.
    Vinh D, Embil J. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005; 5:501–513.PubMedCrossRefGoogle Scholar
  21. 21.
    Carapetis J, Steer A, Mulholland E, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–694.PubMedCrossRefGoogle Scholar
  22. 22.
    Bisno A, Stevens D. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240–245.PubMedCrossRefGoogle Scholar
  23. 23.
    Halpern MT, Schmier JK, Snyder LM et al. Meta-analysis of bacterial resistance to macrolides. J Antimicrob Chemother 2005; 55:748–757.PubMedCrossRefGoogle Scholar
  24. 24.
    Grivea IN, Al-Lahham A, Katopodis GD et al. Resistance to Erythromycin and Telithromycin in Streptococcus pyogenes Isolates Obtained between 1999 and 2002 from Greek Children with Tonsillopharyngitis: Phenotypic and Genotypic Analysis. Antimicrob Agents Chemother 2006; 50:256–261.PubMedCrossRefGoogle Scholar
  25. 25.
    Seppala H, Skurnik M, Soini H et al. The effect of change in consumption of macrolide on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441–446.PubMedCrossRefGoogle Scholar
  26. 26.
    Makhoul IR, Kassis I, Hashman N, Sujov P. Staphylococcal scalded-skin syndrome in a very low birth weight premature infant. Pediatrics 2001; 108:E16.PubMedCrossRefGoogle Scholar
  27. 27.
    Koning S, van der Wouden JC. Treatment for impetigo. BMJ 2004; 329:695–696.PubMedCrossRefGoogle Scholar
  28. 28.
    Koning S, Verhagen AP, van Suijlekom-Smit LW et al. Interventions for impetigo. Cochrane Database Syst Rev 2004:CD003261.Google Scholar
  29. 29.
    Recommandations AFSSAPS: prescription des antibiotiques par voie locale dans les infections cutanées bactériennes primitives et secondaires. Ann Dermatol Venereol 2004; 131:1018–1021.Google Scholar
  30. 30.
    Luby SP, Agboatwalla M, Feikin DR et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366:225–233.PubMedCrossRefGoogle Scholar
  31. 31.
    Chosidow O, Bernard P, Berbis P et al. Cloxacillin versus Pristinamycin for superficial pyodermas: a randomised, open-label, noninferiority study. Dermatology 2005; 210:370–374.PubMedCrossRefGoogle Scholar
  32. 32.
    Perry P, Cook-Bolden F, Rahman Z et al. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol 2002; 46(Suppl 2):S113–119.PubMedCrossRefGoogle Scholar
  33. 33.
    Issartel B, Tristan A, Lechevallier S et al. Frequent carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates from surgically drained abscesses. J ClinMicrobiol 2005; 43:3203–3207.Google Scholar
  34. 34.
    Hoss DM, Feder HM jr. Addition of rifampicin to conventional therapy for recurrent furunculosis. Arch Dermatol 1995; 131:647–648.PubMedCrossRefGoogle Scholar
  35. 35.
    Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. TrendsMicrobiol 2000; 8:369–375.Google Scholar
  36. 36.
    Machado C, Schubach A, Conceiçao-Silva F et al. Botriomycosis. Dermatology 2005; 211:303–304.PubMedCrossRefGoogle Scholar
  37. 37.
    Schneider JA, Parlette HR 3rd. Blistering distal dactylitis: a manifestation of group A beta-hemolytic streptococcal infection. Arch Dermatol 1982; 118:879–880.PubMedCrossRefGoogle Scholar
  38. 38.
    Llewlyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2:156–162.CrossRefGoogle Scholar
  39. 39.
    Acharya KR, Passalacqua EF, Jones EY et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994; 367:94–97.PubMedCrossRefGoogle Scholar
  40. 40.
    Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705–711.PubMedCrossRefGoogle Scholar
  41. 41.
    Kotb M, Norrby-Teglund A, McGeer A et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8:1398–1404.PubMedCrossRefGoogle Scholar
  42. 42.
    Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. J Am Acad Dermatol 1994; 30:319–324.PubMedCrossRefGoogle Scholar
  43. 43.
    Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110:53–60.PubMedGoogle Scholar
  44. 44.
    Amagai M, Matsuyoshi N, Wang ZH et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6:1275–1277.PubMedCrossRefGoogle Scholar
  45. 45.
    Rago JV, Vath GM, Bohach GA et al. Mutational analysis of the superantigen staphylococcal exfoliative toxin A (ETA). J Immunol 2000; 164:2207–2213.PubMedGoogle Scholar
  46. 46.
    Norrby-Teglund A, Thulin P, Gan BS et al. Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis 2001; 184:853–860.PubMedCrossRefGoogle Scholar
  47. 47.
    Mc Cormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu RevMicrobiol 2001; 55:77–104.CrossRefGoogle Scholar
  48. 48.
    Kikuchi K, Takahashi N, Piao C et al. Molecular epidemiologyof methicillin-resistant staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease inneonatal and perinatal wards. J ClinMicrobiol 2003: 41:3001–3006.Google Scholar
  49. 49.
    Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800–807.PubMedCrossRefGoogle Scholar
  50. 50.
    Braun MA, Gerlach D, Hartwig UF et al. Stimulation of human T cells by streptococcal « superantigen » erythrogenic toxins (scarlet fever toxins). J Immunol 1993; 150:2457–2466.PubMedGoogle Scholar
  51. 51.
    Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998; 39:383–398.PubMedCrossRefGoogle Scholar
  52. 52.
    Conférence de consensus: érysipèle et fasciite nécrosante: prise en charge. Ann Dermatol Venereol 2001; 128:307–482.Google Scholar
  53. 53.
    Dupuy A, Benchikhi H, Roujeau JC et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. Br Med J 1999; 318:1591–1594.Google Scholar
  54. 54.
    Estines O, Coste N, Perceau G et al. Érysipèle hémorragique: intérêt d’une courte corticothérapie adjuvante. Ann Dermatol Venereol 2003; 130:523–526.PubMedGoogle Scholar
  55. 55.
    Coste N, Perceau G, Leone J et al. Osteoarticular complications of erysipelas. J Am Acad Dermatol 2004; 50:203–209.PubMedCrossRefGoogle Scholar
  56. 56.
    Bernard P, Bedane C, Mounier M et al. Dermohypodermites bactériennes de l’adulte. Incidence et place de l’étiologie streptococcique. Ann Dermatol Venereol 1995; 122:495–500.PubMedGoogle Scholar
  57. 57.
    Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adult patients: randomised, non-inferiority, open trial. Br Med J 2002; 325:864–866.CrossRefGoogle Scholar
  58. 58.
    Bernard P, Plantin P, Roger H et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127:155–159.PubMedCrossRefGoogle Scholar
  59. 59.
    Hasham S, Matteuci P, Stanley PR, Hart NB. Necrotising fasciitis. Br Med J 2005; 330:830–863.CrossRefGoogle Scholar
  60. 60.
    Pao W, Duncan KO, Bolognia JL et al. Numerous eruptive lesions of panniculitis associated with group A streptococcus bacteremia in an immunocompetent child. Clin Infect Dis 1998; 27:430–433.PubMedCrossRefGoogle Scholar
  61. 61.
    Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J ClinMicrobiol 2001; 39:3727–3732.Google Scholar
  62. 62.
    Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc 2001; 6:170–174.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Ziad Reguiaï
    • 1
  • Philippe Bernard
    • 1
  1. 1.Service de DermatologieHôpital Robert-DebréReims Cedex

Personalised recommendations